Venetoclax with rituximab for relapsed or refractory chronic lymphocytic leukaemia – second and subsequent line

Record ID 32016000820
Authors' recommendations: Chronic lymphocytic leukaemia is a type of cancer which usually develops very slowly. It causes the body to make too many white blood cells called lymphocytes. These lymphocytes are abnormal and do not work properly so build up in the lymph nodes (glands), spleen, bone marrow and blood. Many patients who have chronic lymphocytic leukaemia are diagnosed when having a routine blood test and if they are well, they usually do not need to start treatment straight away. However, if the disease starts to cause symptoms, treatment is then required. Venetoclax is a new type of drug for patients with chronic lymphocytic leukaemia given as a tablet. It is given with a drug called rituximab, which is already used to treat this cancer. Some studies have suggested venetoclax may be helpful for people whose first treatment has failed and whose disease has continued to spread. More studies are now aiming to show how well it works and that it is safe to use. If venetoclax is licensed for use in the UK, it could be a new treatment option for patients with chronic lymphocytic leukaemia that does not need to be injected and may reduce the symptoms of the disease and increase survival.
Project Status: Completed
Year Published: 2016
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: England, United Kingdom
MeSH Terms
  • Sulfonamides
  • Adult
  • Bridged Bicyclo Compounds, Heterocyclic
  • Antineoplastic Agents
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Antineoplastic Combined Chemotherapy Protocols
  • Rituximab
Organisation Name: NIHR Horizon Scanning Centre
Contact Address: The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
Contact Email:
Copyright: NIHR Horizon Scanning Centre (NIHR HSC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.